This is not, at present conventional treatment of beta thalassaemia. However results of studies of allogenic bone marrow transplantation by Lucarelli and his colleagues from Pesaro, Italy have been encouraging.
Reported probabilities of survival, rejection-free survival, death unrelated to rejection and rejection were reported at 0.92, 0.85, 0.06, and 0.08 respectively.
Transplantation-related issues such as graft versus host disease, graft failure, chronic immunosuppressive therapy, and transplantation-related mortality are factors that should be carefully considered prior to proceeding with this approach.
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.